{"id":"https://openalex.org/W7214031860","doi":"https://doi.org/10.1371/journal.pone.0358426","title":"Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain","display_name":"Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain","publication_year":2026,"publication_date":"2026-09-22","ids":{"openalex":"https://openalex.org/W7214031860","doi":"https://doi.org/10.1371/journal.pone.0358426","pmid":"https://pubmed.ncbi.nlm.nih.gov/42771572","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13596810"},"language":"en","primary_location":{"id":"doi:10.1371/journal.pone.0358426","doi":"https://doi.org/10.1371/journal.pone.0358426","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0358426","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0358426&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLOS One","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0358426&type=printable","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Mar\u00eda Lloret Avell\u00e1","orcid":"https://orcid.org/0009-0003-1259-1426","observed_orcids":["https://orcid.org/0009-0003-1259-1426"]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Mar\u00eda Lloret Avell\u00e1","raw_affiliation_strings":["IQVIA"],"raw_orcid":"https://orcid.org/0009-0003-1259-1426","affiliations":[{"raw_affiliation_string":"IQVIA","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mafalda Carmo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mafalda Carmo","raw_affiliation_strings":["IQVIA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IQVIA","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057566677","display_name":"N Duran","orcid":"https://orcid.org/0000-0001-7618-0237","observed_orcids":["https://orcid.org/0000-0001-7618-0237"]},"institutions":[{"id":"https://openalex.org/I114030911","display_name":"Otsuka (Japan)","ror":"https://ror.org/013k5y296","country_code":"JP","type":"company","lineage":["https://openalex.org/I114030911"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"N\u00faria Paladio Duran","raw_affiliation_strings":["Otsuka"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka","institution_ids":["https://openalex.org/I114030911"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5152465857","display_name":"Pere Blancher Parcerisa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114030911","display_name":"Otsuka (Japan)","ror":"https://ror.org/013k5y296","country_code":"JP","type":"company","lineage":["https://openalex.org/I114030911"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Pere Blancher Parcerisa","raw_affiliation_strings":["Otsuka"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka","institution_ids":["https://openalex.org/I114030911"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I28927889"],"apc_list":{"value":2382,"currency":"USD","value_usd":2382},"apc_paid":{"value":2382,"currency":"USD","value_usd":2382},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.65331266,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"21","issue":"9","first_page":"e0358426","last_page":"e0358426"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.8403000235557556,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.8403000235557556,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.09549999982118607,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.04659999907016754,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cedazuridine","display_name":"cedazuridine","score":0.9150000214576721},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":0.8560000061988831},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.9589999914169312},{"id":"https://openalex.org/keywords/route-of-administration","display_name":"route of administration","score":0.6309999823570251},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.5659999847412109},{"id":"https://openalex.org/keywords/hospital-resource-utilization","display_name":"hospital resource utilization","score":0.7319999933242798},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.4399999976158142},{"id":"https://openalex.org/keywords/infection-risk","display_name":"infection risk","score":0.5410000085830688},{"id":"https://openalex.org/keywords/spanish-national-health-system","display_name":"Spanish National Health System","score":0.6809999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.906499981880188},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.6987000107765198},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5691999793052673},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5062999725341797},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.49410000443458557},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.4690000116825104},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.4577000141143799},{"id":"https://openalex.org/C2776093070","wikidata":"https://www.wikidata.org/wiki/Q621636","display_name":"Route of administration","level":2,"score":0.4090000092983246},{"id":"https://openalex.org/C2987404301","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care","level":2,"score":0.40880000591278076},{"id":"https://openalex.org/C3017409249","wikidata":"https://www.wikidata.org/wiki/Q23582796","display_name":"Resource use","level":2,"score":0.39820000529289246},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.3930000066757202},{"id":"https://openalex.org/C2776376669","wikidata":"https://www.wikidata.org/wiki/Q5094647","display_name":"Intensive care unit","level":2,"score":0.3833000063896179},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38179999589920044},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.3605000078678131},{"id":"https://openalex.org/C2776738588","wikidata":"https://www.wikidata.org/wiki/Q1567856","display_name":"Pharmacoeconomics","level":2,"score":0.3573000133037567},{"id":"https://openalex.org/C6964187","wikidata":"https://www.wikidata.org/wiki/Q659256","display_name":"Indirect costs","level":2,"score":0.35109999775886536},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.34040001034736633},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.33180001378059387},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.31790000200271606},{"id":"https://openalex.org/C3019354653","wikidata":"https://www.wikidata.org/wiki/Q5690885","display_name":"Medical costs","level":3,"score":0.3131999969482422},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3122999966144562},{"id":"https://openalex.org/C524218345","wikidata":"https://www.wikidata.org/wiki/Q31218","display_name":"Health economics","level":3,"score":0.30480000376701355},{"id":"https://openalex.org/C27415008","wikidata":"https://www.wikidata.org/wiki/Q7256382","display_name":"Psychological intervention","level":2,"score":0.30219998955726624},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2957000136375427},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.29330000281333923},{"id":"https://openalex.org/C2780724011","wikidata":"https://www.wikidata.org/wiki/Q1295316","display_name":"Emergency department","level":2,"score":0.28619998693466187},{"id":"https://openalex.org/C2776863199","wikidata":"https://www.wikidata.org/wiki/Q976388","display_name":"Acute leukemia","level":3,"score":0.27219998836517334},{"id":"https://openalex.org/C100406419","wikidata":"https://www.wikidata.org/wiki/Q3543802","display_name":"Formulary","level":2,"score":0.26420000195503235},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.26269999146461487},{"id":"https://openalex.org/C2781267111","wikidata":"https://www.wikidata.org/wiki/Q652297","display_name":"Catheter","level":2,"score":0.25029999017715454}],"mesh":[{"descriptor_ui":"D000077209","descriptor_name":"Decitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000077209","descriptor_name":"Decitabine","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013030","descriptor_name":"Spain","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014529","descriptor_name":"Uridine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D061605","descriptor_name":"Administration, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1371/journal.pone.0358426","doi":"https://doi.org/10.1371/journal.pone.0358426","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0358426","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0358426&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLOS One","raw_type":"journal-article"},{"id":"pmid:42771572","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42771572","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PloS one","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13596810","doi":null,"is_oa":true,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42771572/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS One","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:4acd2fe1ea334065a9e838be94849ba0","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/4acd2fe1ea334065a9e838be94849ba0","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"PLoS ONE, Vol 21, Iss 9, p e0358426 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1371/journal.pone.0358426","doi":"https://doi.org/10.1371/journal.pone.0358426","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0358426","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0358426&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLOS One","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320324177","display_name":"Otsuka Pharmaceutical","ror":"https://ror.org/013k5y296"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7214031860.pdf","grobid_xml":"https://content.openalex.org/works/W7214031860.grobid-xml"},"referenced_works_count":14,"referenced_works":["https://openalex.org/W2058188142","https://openalex.org/W2472310215","https://openalex.org/W2966881177","https://openalex.org/W4221007142","https://openalex.org/W4225299329","https://openalex.org/W4293253058","https://openalex.org/W4375864377","https://openalex.org/W4376223818","https://openalex.org/W4389100296","https://openalex.org/W4402816183","https://openalex.org/W4408412862","https://openalex.org/W4409700974","https://openalex.org/W4415732301","https://openalex.org/W7126064641"],"related_works":["https://openalex.org/W7046892043","https://openalex.org/W4402314937","https://openalex.org/W7112453921","https://openalex.org/W2626355247","https://openalex.org/W4390126227","https://openalex.org/W4417002159","https://openalex.org/W7220988410","https://openalex.org/W4399487044","https://openalex.org/W3092245026","https://openalex.org/W4393051023"],"abstract_inverted_index":{"Acute":[0],"myeloid":[1],"leukemia":[2],"(AML)":[3],"primarily":[4],"affects":[5],"older":[6],"adults,":[7],"many":[8],"of":[9,68,86,127,174,205,219,271,284],"whom":[10],"are":[11,26],"unsuitable":[12],"for":[13,79,143,159,163,168,178],"intensive":[14,81],"chemotherapy.":[15],"Hypomethylating":[16],"agents":[17],"(HMA)":[18],"-intravenous":[19],"(IV)":[20],"decitabine":[21],"and":[22,35,54,61,65,71,110,118,134,145,166,176,183,202,227,239,247,258,266],"subcutaneous":[23],"(SC)":[24],"azacitidine-":[25],"standard":[27,80],"therapeutic":[28],"options":[29],"but":[30],"require":[31],"frequent":[32],"hospital":[33,51,260],"visits":[34],"substantial":[36],"healthcare":[37,129,220],"resource":[38,52,213],"use.":[39],"Oral":[40,208,251],"decitabine/cedazuridine":[41],"(DEC-C)":[42],"offers":[43],"a":[44,125,275],"therapeutically":[45],"equivalent":[46],"alternative":[47],"that":[48],"may":[49],"reduce":[50],"burden":[53],"improve":[55],"patient":[56,156],"convenience.":[57],"This":[58],"study":[59],"estimated":[60],"compared":[62],"the":[63,84,87,102,203,269,282],"economic":[64],"organizational":[66,264],"impact":[67],"IV,":[69],"SC,":[70,184],"oral":[72,169,179,286],"HMA":[73],"administration":[74,103,252],"in":[75,192],"AML":[76,272],"patients":[77],"unfit":[78],"chemotherapy,":[82],"from":[83,124],"perspective":[85],"Spanish":[88],"National":[89],"Health":[90],"System.":[91],"A":[92],"micro\u2011costing":[93],"model":[94],"quantified":[95],"direct":[96,255],"non\u2011pharmacological":[97],"costs":[98,150,154,257],"associated":[99],"solely":[100],"with":[101],"route":[104],"across":[105,131],"five":[106],"domains:":[107],"drug":[108,148],"preparation":[109],"administration,":[111],"treatment\u2011related":[112],"hospitalizations,":[113],"medical":[114],"transportation,":[115],"catheter":[116],"management,":[117],"infections.":[119],"Resource":[120],"use":[121,235],"was":[122],"derived":[123],"survey":[126],"30":[128],"professionals":[130],"16":[132],"hospitals":[133],"valued":[135],"using":[136],"official":[137],"tariffs.":[138],"Costs":[139],"were":[140,151,157,187],"calculated":[141],"separately":[142],"induction":[144],"subsequent":[146],"cycles;":[147],"acquisition":[149],"excluded.":[152],"Non\u2011pharmacological":[153],"per":[155,232],"\u20ac9,998":[158],"IV":[160,182,246],"decitabine,":[161],"\u20ac12,177":[162],"SC":[164],"azacitidine,":[165],"\u20ac1,306":[167],"DEC\u2011C,":[170],"representing":[171],"cost":[172],"reductions":[173,191],"87%":[175,244],"89%":[177],"therapy":[180,209],"versus":[181,245,249],"respectively.":[185],"Savings":[186],"driven":[188],"mainly":[189],"by":[190,237,243],"hospitalization":[193],"(58-61%),":[194],"transport":[195],"(13-22%),":[196],"infections":[197],"(9%-12%),":[198],"administration\u2011related":[199],"activities":[200],"(11-12%)":[201],"avoidance":[204],"catheter-related":[206],"costs.":[207],"also":[210],"markedly":[211],"reduced":[212],"utilization,":[214],"including":[215],"40-50":[216],"fewer":[217,224,229],"hours":[218],"professional":[221],"time,":[222],"8-9":[223],"inpatient":[225],"days,":[226],"4-8":[228],"ambulance":[230],"transfers":[231],"patient.":[233],"Catheter":[234],"decreased":[236],"33%,":[238],"infection":[240],"risk":[241],"declined":[242],"54%":[248],"SC.":[250],"substantially":[253],"reduces":[254],"non\u2011drug":[256],"frees":[259],"capacity,":[261],"offering":[262],"meaningful":[263],"efficiencies":[265],"contributing":[267],"to":[268],"sustainability":[270],"care":[273],"within":[274],"resource\u2011constrained":[276],"health":[277],"system.":[278],"These":[279],"findings":[280],"reinforce":[281],"value":[283],"integrating":[285],"HMAs":[287],"into":[288],"clinical":[289],"pathways.":[290]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-09-23T00:00:00"}